December 11, 2025

Regulatory-Driven Weighted Valuation — LDX

1. Scenario Valuations (Per Share)

These are the intrinsic values under each outcome:

• Bear Case (Regulatory failure or multi-year delay): A$0.10
• Base Case (CLIA waiver granted; standard adoption curve): A$0.22
• Bull Case (CLIA waiver granted + favourable reimbursement + faster uptake): A$0.42

2. Regulatory-Driven Probabilities

Weights are assigned based primarily on regulatory risk, not commercial execution.

Given LDX’s current position (late-stage CLIA submission, strong data, clear FDA pathway), a rational regulatory weighting is:

• Bear Probability: 10%
• (Regulatory failure or material delay)
• Base Probability: 60%
• (Approval with typical adoption)
• Bull Probability: 30%
• (Approval + reimbursement momentum + strong early adoption)

These numbers reflect that the major binary risk = CLIA approval, and that probability is now well above 50%, but not certain.

3. Weighted Valuation Calculation

Bear: 0.10 × 0.10 = 0.010

Base: 0.22 × 0.60 = 0.132

Bull: 0.42 × 0.30 = 0.126

Regulatory-Weighted Valuation for LDX

= A$0.27 per share

4. Interpretation

• A $0.27/sh regulatory-weighted valuation reflects a world where regulatory approval is the dominant driver, not commercial scale.
• The valuation sits between the base and bull cases, consistent with high regulatory confidence.
• It is above the simple weighted valuation (~$0.24) because regulatory success now carries 90% of the weighted probability.

Updated Valuation - April 2, 2026

Lumos Diagnostics (ASX: LDX) — Valuation

Lumos has now crossed the key inflection points: CLIA waiver secured, capital raised, and first meaningful commercial order delivered. The investment case shifts from binary regulatory risk to execution — specifically site rollout and utilisation.

The question is no longer “does FebriDx get approved?” It is now “does FebriDx get used?”

Framework

Valuation is built bottom-up, anchored to:

• US rollout (sites onboarded)
• Utilisation (tests per site)
• Pricing (~A$30/test)
• Benchmarking vs POC diagnostics comps (Quidel, BD, Abbott)
• Risk-adjusted FCF outcomes

Scenario Analysis

Bear Case — A$0.10–0.15

This assumes rollout underdelivers:

• <10k active sites
• Low utilisation (150–300 tests/site/year)
• Limited repeat ordering / weak clinical adoption

In this scenario, FebriDx fails to embed into routine workflows. Revenue scales, but not enough to justify the installed base. This is effectively a distribution success but utilisation failure.

Base Case — A$0.30–0.40

This reflects a credible execution path:

• ~20k sites over 5–7 years
• 400–700 tests/site/year
• Adoption in line with mid-range POC diagnostics comps
• Gradual reimbursement support

This is not heroic — it assumes FebriDx becomes a useful, but not universal, clinical tool. This is the most realistic outcome based on comparable platforms.

Bull Case — A$0.70–1.00+

Requires strong commercial execution:

• 30k+ sites
• 800–1,000+ tests/site/year
• Evidence of routine use (not just trialing)
• Reimbursement and guideline support

Here, FebriDx becomes embedded in frontline decision-making. This is where operating leverage drives material upside.

Probability Weighting

With CLIA risk removed and early commercial traction visible:

• Bear: 10%
• Base: 60%
• Bull: 30%

The recent PHASE Scientific order is important — not for its size, but because it confirms the start of the rollout curve. It reduces early-stage execution risk but does not yet prove scale.

Valuation

Using midpoints:

• Bear: 0.125 × 10% = 0.013
• Base: 0.35 × 60% = 0.210
• Bull: 0.85 × 30% = 0.255

Weighted (steady-state): ~A$0.48 per share

Discount to Present Value

This value sits several years out and requires execution. Applying a discount for:

• Time to scale (5–7 years)
• Adoption uncertainty
• Residual execution risk

Fair Value (today): A$0.28–0.32 per share

Interpretation

• The recent raise (~A$0.225) effectively sets a near-term floor
• Current valuation implies partial belief in the base case, but limited credit for scale
• Upside exists, but is now conditional on utilisation, not access

Key KPI

If there is one metric that matters:

Tests per site per month

• <20 → rollout is stalling
• 40–60 → base case intact
• 80+ → bull case forming

Everything else (orders, headlines, partnerships) is secondary to this.

Bottom Line

LDX has de-risked meaningfully, but it has not yet proven the model.

• Downside is now more contained
• Base case is credible
• Upside remains significant, but earned

This is now a commercial scaling story, not a regulatory binary bet.